VECTOR DEVELOPMENT AND PRODUCTION CORE FACILITY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 载体核心指导肿瘤逆转录病毒、慢病毒和重组AAV载体的生产。病毒载体生产设施通过集中重组病毒载体生产的生产，最大限度地提高资源利用率和效率，因此，所有这些工作都使用标准方案和TNPRC所推行的所有基因治疗项目相同的严格指南来完成。通过提供媒介核心服务，VDPC不仅将对基因治疗计划产生重大影响，还将对TNPRC内的比较病理学、微生物学和免疫学等其他部门，以及杜兰健康科学中心和路易斯安那州立大学健康科学中心内的部门和中心产生重大影响。在微生物和免疫学司的合作下，VDPC已经开始与TNPRC的研究人员一起生成表达重组蛋白的载体。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Vector Core directs the production of the oncoretrovirus, lentivirus, and recombinant AAV vectors. The virus vector production facility maximizes resource utilization and efficiency by centralizing the production of recombinant virus vector production, such that it is all done using standard protocols and the same strict guidelines for all of the gene therapy projects that are pursued at TNPRC. By providing vector core services, the VDPC will have a large impact not only on the Gene Therapy Program, but on other divisions such as Comparative Pathology, Microbiology and Immunology within the TNPRC, but also Departments and Centers within the Tulane Health Sciences Center and Louisiana State University Health Sciences Center. In collaboration with the Division of Microbiology and Immunology, the VDPC has begun to generate vectors that express recombinant proteins with investigators at the TNPRC.